ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Patients Who Smoke In Treatment Do Worse Than Those Who Quit

March 25, 2011

In Brief: Kennedy’s Oversight Hearings Will Include Cancer Program, Important To Act Renewal

January 26, 1979

DHEA- Sulfate Said To Prevent Breast Cancer, Overweight

March 28, 1980

Dial Access Offers Caner Consultation Services

February 21, 1975

DeVita, Seffrin Present Cancer Czar PlanTo Feinstein, Without Committee Sign-Off

June 1, 2001

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014